PACB

$1.33-0.07 (-5.00%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Pacific Biosciences of California, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.33
Potential Upside
5%
Whystock Fair Value$1.40
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technolo...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$401.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-9840.33%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.47

Recent News

Zacks
Mar 20, 2026

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.33, denoting a -5% move from the preceding trading day.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 19, 2026

3 Small-Cap Stocks with Warning Signs

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 18, 2026

Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?

Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 17, 2026

Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
StockStory
Mar 13, 2026

3 of Wall Street’s Favorite Stocks We Think Twice About

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.